Knights of Columbus Asset Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-13,210
Closed -$756K 399
2024
Q3
$756K Sell
13,210
-83,223
-86% -$4.77M 0.05% 251
2024
Q2
$5.05M Buy
96,433
+1,106
+1% +$48.5K 0.33% 100
2024
Q1
$3.88M Sell
95,327
-90,518
-49% -$3.39M 0.28% 124
2023
Q4
$6.87M Buy
185,845
+92,552
+99% +$3.49M 0.44% 62
2023
Q3
$3.56M Buy
93,293
+13,352
+17% +$547K 0.33% 98
2023
Q2
$2.88M Buy
79,941
+195
+0.2% +$6.65K 0.26% 119
2023
Q1
$3.05M Buy
79,746
+5,039
+7% +$236K 0.3% 117
2022
Q4
$4.25M Sell
74,707
-15,953
-18% -$817K 0.44% 69
2022
Q3
$3.58M Buy
90,660
+6,903
+8% +$305K 0.37% 89
2022
Q2
$3.69M Buy
83,757
+32,355
+63% +$1.4M 0.37% 87
2022
Q1
$2.05M Buy
51,402
+589
+1% +$21K 0.18% 184
2021
Q4
$2.04M Buy
50,813
+832
+2% +$31.1K 0.17% 187
2021
Q3
$2.03M Buy
+49,981
New +$2.09M 0.18% 184

Other funds holding HALO

Knights of Columbus Asset Advisors's HALO Position: Q4 2024 in Review

Knights of Columbus Asset Advisors sold out of Halozyme (HALO) in Q4 2024, closing a stake of 13,210 shares — an estimated $756K sold.

Knights of Columbus Asset Advisors first reported a position in HALO in Q3 2021 and held it in 13 quarters. The position peaked at $6.87M in Q4 2023. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

  • Knights of Columbus Asset Advisors reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
  • Knights of Columbus Asset Advisors sold 13,210 Halozyme shares in Q4 2024, an estimated $756K.
  • Knights of Columbus Asset Advisors first reported a position in Halozyme in Q3 2021 and held it in 13 quarters.
  • Knights of Columbus Asset Advisors's Halozyme position peaked at $6.87M in Q4 2023.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on Knights of Columbus Asset Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.